Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings
To compare the absolute bioavailability of phenytoin (PHT) sodium solution and PHT acid suspension in healthy volunteers receiving continuously infused enteral feedings. Randomized, open-label, single-dose, three-period crossover study. University clinical research center. Ten healthy volunteers age...
Saved in:
Published in | Pharmacotherapy Vol. 18; no. 3; p. 637 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.05.1998
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | To compare the absolute bioavailability of phenytoin (PHT) sodium solution and PHT acid suspension in healthy volunteers receiving continuously infused enteral feedings.
Randomized, open-label, single-dose, three-period crossover study.
University clinical research center.
Ten healthy volunteers age 23-43 years.
The three phases of the study were separated by at least 7 days. During phase A, subjects received PHT sodium 435 mg intravenously over 30 minutes. During phases B and C, subjects had a nasogastric feeding tube placed through which PHT acid suspension 400 mg and PHT sodium solution 435 mg were administered, respectively. For phases B and C, continuous enteral feedings were given by feeding tube for 14 hours before and after the PHT dose. Blood samples were collected over 72 hours after each PHT dose, and the serum was analyzed for PHT.
The rate and extent of PHT absorption and PHT pharmacokinetics were determined using an empirical quadratic function of time method. Bioavailability, rate of absorption, maximum concentration (Cmax), and time to maximum concentration (Tmax) were compared for the two enteral doses by paired Student's t test. There were no significant differences in bioavailability for PHT acid suspension and PHT sodium solution (0.88 +/- 0.15 vs 0.91 +/- 0.7, p=0.57, 90% CI -0.14-0.071). The Cmax was greater (7.4 +/- 0.9 mg/L vs 5.5 +/- 1.7 mg/L, p=0.019) and Tmax was less (2.5 +/- 3.8 vs.14.8 +/- 11.2 hrs, p=0.004) for the sodium solution. The time to 50% fractional absorption (0.33 +/- 0.08 vs 3.2 +/- 2.4 hrs, p=0.004) and 90% fractional absorption (7.9 +/- 6.2 vs 22.3 +/- 17.2 hrs, p=0.021) was also significantly shorter for the sodium solution.
The absolute bioavailability of the two dosage forms of PHT administered with concomitant enteral feedings were not significantly different, however, the absorption patterns were significantly different, with the sodium solution being more rapidly absorbed. |
---|---|
AbstractList | To compare the absolute bioavailability of phenytoin (PHT) sodium solution and PHT acid suspension in healthy volunteers receiving continuously infused enteral feedings.
Randomized, open-label, single-dose, three-period crossover study.
University clinical research center.
Ten healthy volunteers age 23-43 years.
The three phases of the study were separated by at least 7 days. During phase A, subjects received PHT sodium 435 mg intravenously over 30 minutes. During phases B and C, subjects had a nasogastric feeding tube placed through which PHT acid suspension 400 mg and PHT sodium solution 435 mg were administered, respectively. For phases B and C, continuous enteral feedings were given by feeding tube for 14 hours before and after the PHT dose. Blood samples were collected over 72 hours after each PHT dose, and the serum was analyzed for PHT.
The rate and extent of PHT absorption and PHT pharmacokinetics were determined using an empirical quadratic function of time method. Bioavailability, rate of absorption, maximum concentration (Cmax), and time to maximum concentration (Tmax) were compared for the two enteral doses by paired Student's t test. There were no significant differences in bioavailability for PHT acid suspension and PHT sodium solution (0.88 +/- 0.15 vs 0.91 +/- 0.7, p=0.57, 90% CI -0.14-0.071). The Cmax was greater (7.4 +/- 0.9 mg/L vs 5.5 +/- 1.7 mg/L, p=0.019) and Tmax was less (2.5 +/- 3.8 vs.14.8 +/- 11.2 hrs, p=0.004) for the sodium solution. The time to 50% fractional absorption (0.33 +/- 0.08 vs 3.2 +/- 2.4 hrs, p=0.004) and 90% fractional absorption (7.9 +/- 6.2 vs 22.3 +/- 17.2 hrs, p=0.021) was also significantly shorter for the sodium solution.
The absolute bioavailability of the two dosage forms of PHT administered with concomitant enteral feedings were not significantly different, however, the absorption patterns were significantly different, with the sodium solution being more rapidly absorbed. |
Author | Doak, K K Reiser, J R Altavela, J L Dunnigan, K J Huntress, J Reiss, R A Haas, C E |
Author_xml | – sequence: 1 givenname: K K surname: Doak fullname: Doak, K K organization: Department of Pharmacy Practice, School of Pharmacy, State University of New York at Buffalo, USA – sequence: 2 givenname: C E surname: Haas fullname: Haas, C E – sequence: 3 givenname: K J surname: Dunnigan fullname: Dunnigan, K J – sequence: 4 givenname: R A surname: Reiss fullname: Reiss, R A – sequence: 5 givenname: J R surname: Reiser fullname: Reiser, J R – sequence: 6 givenname: J surname: Huntress fullname: Huntress, J – sequence: 7 givenname: J L surname: Altavela fullname: Altavela, J L |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/9620116$$D View this record in MEDLINE/PubMed |
BookMark | eNpNj81Kw0AURmdRqW31EYTBfeLcm8nMZKlFqxBwo-tyMz92SjIpTarm7RXswtUHh8OBb8lmqU-esVsQOQiBd_scjC6zCkDmUFUmHxtRAJr8e8YWArXOhBDmki2HYf_rg5I4Z_NKoQBQC1Y_xJ4-KbbUxDaOE-8DP-x8msY-Jk42Ok7J_UND7-Kp419x3HGfRn-klgfvXUwfwxW7CNQO_vq8K_b-9Pi2fs7q183L-r7OrCyMyQhtYyBoUGVhHSgtS3QNeUArrJOEwZSGNJYApfMBSSoVCl0VVjoIZHDFbv66h1PTebc9HGNHx2l7foU_K_hSEw |
CitedBy_id | crossref_primary_10_1177_0884533608326060 crossref_primary_10_1002_ncp_10615 crossref_primary_10_1002_phar_1589 crossref_primary_10_1016_j_ejps_2009_02_003 crossref_primary_10_1016_j_ijpharm_2018_01_005 crossref_primary_10_1097_FTD_0b013e3181d3fa3e crossref_primary_10_1002_ncp_11051 crossref_primary_10_1097_00044067_200011000_00009 crossref_primary_10_1016_j_ejps_2008_01_014 crossref_primary_10_1016_j_curtheres_2007_10_007 crossref_primary_10_1016_j_ijpharm_2018_07_042 crossref_primary_10_1345_aph_19355 crossref_primary_10_1592_phco_22_5_329_33192 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/j.1875-9114.1998.tb03128.x |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 9620116 |
Genre | Research Support, U.S. Gov't, P.H.S Comparative Study Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NCRR NIH HHS grantid: RR00044 |
GroupedDBID | --- .GJ .Y3 05W 0R~ 0VX 123 1CY 1OB 1OC 31~ 33P 34G 39C 3SF 4.4 50Z 52U 52V 53G 5RE 8-0 8-1 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAXRX AAYOK AAZKR ABCUV ABJNI ABLJU ABOCM ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BRXPI CGR CS3 CUY CVF DCZOG DPXWK DRFUL DRMAN DRSTM DU5 EBD EBS ECM EIF EJD EMOBN F5P FEDTE FUBAC G-S GODZA GWYGA H.X HGLYW HVGLF HZ~ J5H KBYEO LATKE LEEKS LH4 LITHE LOXES LSO LUTES LW6 LYRES MEWTI MJL MK0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N04 N05 NF~ NPM O66 O9- P2P P2W PALCI PQQKQ Q.N QB0 R.K RIWAO RJQFR ROL SAMSI SJN SUPJJ SV3 TUS TWZ UDS WBKPD WHWMO WIH WIJ WIK WOHZO WVDHM WXSBR YCJ ZGI ZXP ZZTAW ~WT |
ID | FETCH-LOGICAL-c4388-a2cb81f71653cd167452dbae12c0cd4a2f858a725115def2a466f3793c4d1fa82 |
ISSN | 0277-0008 |
IngestDate | Sat Sep 28 07:41:06 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4388-a2cb81f71653cd167452dbae12c0cd4a2f858a725115def2a466f3793c4d1fa82 |
PMID | 9620116 |
ParticipantIDs | pubmed_primary_9620116 |
PublicationCentury | 1900 |
PublicationDate | May‐June 1998 |
PublicationDateYYYYMMDD | 1998-05-01 |
PublicationDate_xml | – month: 05 year: 1998 text: May‐June 1998 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Pharmacotherapy |
PublicationTitleAlternate | Pharmacotherapy |
PublicationYear | 1998 |
SSID | ssj0021642 |
Score | 1.6836259 |
Snippet | To compare the absolute bioavailability of phenytoin (PHT) sodium solution and PHT acid suspension in healthy volunteers receiving continuously infused enteral... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 637 |
SubjectTerms | Adult Anticonvulsants - administration & dosage Anticonvulsants - pharmacokinetics Biological Availability Enteral Nutrition Female Food-Drug Interactions Humans Injections, Intravenous Male Phenytoin - administration & dosage Phenytoin - pharmacokinetics |
Title | Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings |
URI | https://www.ncbi.nlm.nih.gov/pubmed/9620116 |
Volume | 18 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8NAFB5cELyIK-7MQbxo1EwmyeToSnFDpII3mcwiAdsIrUL99b6XmTa1Ki6XEGYgtPleXt73Zr4vhGxxAxwh02mQqQMTcM2yQOiUBVrnaZSIXNjK8ebqOmnc8fP7-H5EXdLN99Tbl7qS_6AKY4ArqmT_gOzgojAA54AvHAFhOP4K46OilK-yeHJe29VaOW7Z6nXLor0jVaGdDcBgqFPq4qXleq_oxYnifOteX53hKvXG-1l3P1oOnJSyyp0XdW-0IZ0gbEjRgCVx8ej6qhf1qtOtKdz32W99-1TX2rv-xj6fkXC9F6uGr9Nnza6rXJg4N5dPOdp5vkKOBqqEuZajYlJgizqCl6XbvTkE3nOrQi9LsFRJfpwccc_2M-NkPBWYAK-xmeP5ODDFapGp_69qT9r973_dNJny1xwhIlVB0pwlM55J0EMXFnNkzLTnybaHrrdLm7WyrrNLt-lNbVLeWyCXI7FDS0sHgUIxdijEztCQix2KsUN97NB-7CySu7PT5nEj8F_WCBSP4CGSTOUitMCV40hpFKLETOfShEwdKM0lsyIWMkX6GWtjmeRJYiNI5Yrr0ErBlshEu2ybZUI1gwspIPnChNwanmkGVWaY5DqSIpPxCllyd-nh2dmnPPjbt_rdxBqZroNvnUxaeFrNBpR-3XyzAvAdJntUlA |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bioavailability+of+phenytoin+acid+and+phenytoin+sodium+with+enteral+feedings&rft.jtitle=Pharmacotherapy&rft.au=Doak%2C+K+K&rft.au=Haas%2C+C+E&rft.au=Dunnigan%2C+K+J&rft.au=Reiss%2C+R+A&rft.date=1998-05-01&rft.issn=0277-0008&rft.volume=18&rft.issue=3&rft.spage=637&rft_id=info:doi/10.1002%2Fj.1875-9114.1998.tb03128.x&rft_id=info%3Apmid%2F9620116&rft_id=info%3Apmid%2F9620116&rft.externalDocID=9620116 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0277-0008&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0277-0008&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0277-0008&client=summon |